Replies to post #685977 on ORIONS Money Stocks

[georgie18]

IMRX...$3.11...🥳...https://finviz.com/news/82017/immuneering-reports-positive-overall-survival-data-for-atebimetinib-imm-1-104-from-ongoing-phase-2a-trial-in-first-line-pancreatic-cancer-patients

georgie18

Member Level
Re: georgie18 post# 137

Monday, June 16, 2025 1:32:33 PM

Post#
138
of 138
IMRX...$2.35...🥳

georgie18

Member Level
Re: georgie18 post# 389758

Monday, June 16, 2025 8:31:26 AM

Post#
394384
of 394426
IMRX...$2.15...🥳... CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.

The conference call will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.